MiraMSC

AssetAlso called MiraMSC-FS-001

Allogeneic umbilical cord-derived mesenchymal stem cell therapy intended to treat frailty.

Stage
Phase 1
Modality
Cell therapy
Target
Not known
1
Indication
1
Trial
1
Developer

Trial NCT07705464 is still running. Trial NCT07705464 updated in its registry on Jul 15, 2026. clinicaltrials.gov

Indications

1

In the full profile

  • Owner and partners1
  • Trials1
  • Competitors3
  • Aging relevance2
  • Signals1

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets